Literature DB >> 21390515

Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma.

Ying-Jie Zhu1, Yue-Li Sun, Yi Xia, Wen-Qi Jiang, Jia-Jia Huang, Hui-Qiang Huang, Tong-Yu Lin, Zhong-Zhen Guan, Zhi-Ming Li.   

Abstract

The aim of our study is to investigate the clinical characteristics and prognostic factors in Chinese Hodgkin's lymphoma patients. It is known that clinical characteristics and epidemiology of Hodgkin's lymphoma in China are different from Western countries. In total, 137 consecutive, previously untreated patients with Hodgkin's lymphoma at Sun Yat-Sen University Cancer Center were enrolled. Among these patients, 92 were male and 45 were female, with a median age of 28 (range: 2-76) years. The bimodal age curve of classical Hodgkin's lymphoma analyzed from our patients was not obvious as the Western population, showing an early peak in 25 years and a second peak in 45 years. Most of the patients (41.6%) were classified as nodular sclerosis classic Hodgkin's lymphoma. Results showed that the 5-year overall survival, event-free survival, and disease-free survival rates were 97.7, 85.0, and 94.0%, respectively. Lymphopenia at diagnosis was related to poorer overall survival (P = 0.015) and event-free survival (P < 0.001) in all-stage Hodgkin's lymphoma patients. Multivariate analysis showed that lymphopenia as an independent unfavorable prognostic factor influenced event-free survival (P = 0.015). The international prognostic score ≥ 5 was also the only independent prognostic factor of disease-free survival in advanced-stage patients (P = 0.046). Our findings demonstrated that some clinical characteristics of Hodgkin's lymphoma in China were different from those in the Western countries. Lymphopenia was an effective prognostic predictor in both early stage and advanced stage.

Entities:  

Mesh:

Year:  2011        PMID: 21390515     DOI: 10.1007/s12032-011-9902-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

Authors:  Evert M Noordijk; Patrice Carde; Noëlle Dupouy; Anton Hagenbeek; Augustinus D G Krol; Johanna C Kluin-Nelemans; Umberto Tirelli; Mathieu Monconduit; José Thomas; Houchingue Eghbali; Berthe M P Aleman; Jacques Bosq; Marjeta Vovk; Tom A M Verschueren; Anne-Marie Pény; Théodore Girinsky; John M M Raemaekers; Michel Henry-Amar
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

3.  Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma.

Authors:  D H Kim; J H Baek; Y S Chae; Y-K Kim; H J Kim; Y H Park; H S Song; J S Chung; M S Hyun; S K Sohn
Journal:  Leukemia       Date:  2007-06-07       Impact factor: 11.528

4.  Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.

Authors:  Yasuhiro Oki; Kazuhito Yamamoto; Harumi Kato; Yachiyo Kuwatsuka; Hirofumi Taji; Yoshitoyo Kagami; Yasuo Morishima
Journal:  Eur J Haematol       Date:  2008-08-06       Impact factor: 2.997

5.  Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group.

Authors:  J Franklin; U Paulus; D Lieberz; K Breuer; H Tesch; V Diehl
Journal:  Ann Oncol       Date:  2000-05       Impact factor: 32.976

6.  Absolute lymphocyte count predicts overall survival in follicular lymphomas.

Authors:  Mustaqeem Siddiqui; Kay Ristow; Svetomir N Markovic; Thomas E Witzig; Thomas M Habermann; Joseph P Colgan; David J Inwards; William L White; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Timothy G Call; Luis F Porrata
Journal:  Br J Haematol       Date:  2006-08-01       Impact factor: 6.998

7.  Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group.

Authors:  A Josting; U Rueffer; J Franklin; M Sieber; V Diehl; A Engert
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

8.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group.

Authors:  M Henry-Amar; S Friedman; M Hayat; R Somers; J H Meerwaldt; P Carde; J M Burgers; J Thomas; M Monconduit; E M Noordijk
Journal:  Ann Intern Med       Date:  1991-03-01       Impact factor: 25.391

10.  Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.

Authors:  R García; J M Hernández; M D Caballero; M González; J Galende; M C del Cañizo; L Vázquez; J F San Miguel
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

View more
  4 in total

1.  Impact on the survival of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and monocyte-lymphocyte ratio on prognosis in children with Hodgkin lymphoma.

Authors:  Kubra Ertan; Aysenur Dogru; Buket Kara; Yavuz Koksal
Journal:  Saudi Med J       Date:  2022-05       Impact factor: 1.422

2.  Cancer Burden in China during 1990-2019: Analysis of the Global Burden of Disease.

Authors:  Shu-Zhen Zhang; Li Zhang; Long Xie
Journal:  Biomed Res Int       Date:  2022-04-14       Impact factor: 3.246

3.  Applicability of protocols from high-income countries in a resource limited setting; real world data of histopathology, clinical features and long-term outcome of Hodgkin Lymphoma in Sri Lanka.

Authors:  Saman Hewamana; Lakmali Kandabadage; Thurairajah Skandarajah; Natasha Peiris; Sobitha Abeyaratne; Gehan Arseculeratne; Eranga Perera; Mahesh Harischandra; Ananda Wijewickrama; Gnani Somasundaram; Vadivelu Srinivasan; Surjit Somiah; Priyankara Jayawardena; Rohini Wadanamby; Geethani Galagoda; Chathuri Jayasinghe; Chandu De Silva; Sanjeewa Munasinghe; Bandula Wijesiriwardena; Jayantha Balawardena
Journal:  EClinicalMedicine       Date:  2021-07-06

4.  Clinical features and treatment outcomes of Hodgkin's lymphoma in Hong Kong Chinese.

Authors:  Man Fai Law; Ting Ying Ng; Hay Nun Chan; Ho Kei Lai; Chung Yin Ha; Charlotte Leung; Celia Ng; Yiu Ming Yeung; Sze Fai Yip
Journal:  Arch Med Sci       Date:  2014-06-27       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.